Vertex Pharmaceuticals Inc / Ma (VRTX) revenue: $12B
Vertex Pharmaceuticals Inc / Ma reported $12B of revenue for the year ended Dec 31, 2025, up 8.9% from $11B a year earlier.
From Vertex Pharmaceuticals Inc / Ma's filings with the SEC · Read the filing · VRTX stock page
Vertex Pharmaceuticals Inc / Ma revenue by year
#384 of 3,623 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $12B | +9% |
| Dec 31, 2024 | $11B | +12% |
| Dec 31, 2023 | $9.9B | +11% |
| Dec 31, 2022 | $8.9B | +18% |
| Dec 31, 2021 | $7.6B | – |
Revenue of similar companies
Companies in the same industry as Vertex Pharmaceuticals Inc / Ma, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| TEVA Pharmaceutical Industries | $17.3B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $14.3B | Dec 31, 2025 |
| Viatris | $14.3B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12B | Dec 31, 2025 |
| Bausch Health Companies | $10.3B | Dec 31, 2025 |
| Zoetis | $9.5B | Dec 31, 2025 |
| Organon | $6.2B | Dec 31, 2025 |
Questions and answers
What is Vertex Pharmaceuticals Inc / Ma's revenue?
Vertex Pharmaceuticals Inc / Ma reported $12B of revenue for the year ended Dec 31, 2025, up 8.9% from $11B a year earlier.
Numbers as reported in Vertex Pharmaceuticals Inc / Ma's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology